The company did not provide specific financial guidance for the current or future periods.
Cost drivers
R&D costs fell — Atossa said lower Q2 R&D professional fees were mainly due to completion of preclinical trials for (Z)-endoxifen, though R&D compensation rose.
Clinical trial enrollment — The company reported increased clinical trial expenses due to higher enrollment and drug development costs for (Z)-endoxifen.
Legal fees — Higher general and administrative expenses were due to increased legal fees related to patent litigation and compliance.
Analyst coverage and price target
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the biotechnology and medical research peer group is .
ATOS•
